|
Category: antidandruff, antimicrobial agents
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| logP (o/w): | 4.770 |
| Soluble in: |
| | water, 0.9008 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-dog LD50 > 500 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 739, 1983.
intravenous-mouse LD50 57 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 23, 1984.
oral-mouse LD50 2629 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 739, 1983.
oral-rabbit LD50 4000 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 739, 1983.
intravenous-rat LD50 63 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 23, 1984.
oral-rat LD50 1463 mg/kg SKIN AND APPENDAGES (SKIN): HAIR: OTHER
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 23, 1984.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 > 15000 mg/kg BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 23, 1984.
subcutaneous-rat LD50 > 10000 mg/kg BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 23, 1984.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | antidandruff, antimicrobial agents |
| Recommendation for bifonazole usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for bifonazole flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | azolmen | | | bifazol | | | bifonazol | | | bifonazolum | | 1-((4- | biphenylyl)phenylmethyl)-1H-imidazole | | | canespor | | (+-)-1-(p,alpha- | diphenylbenzyl)imidazole | | 1H- | imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)- | | 1H- | imidazole, 1-[(1,1'-biphenyl)-4-ylphenylmethyl]- | | | mycospor | | 1-[ | phenyl-(4-phenylphenyl)methyl]imidazole | | | trifonazole |
Articles:
|